Dare Bioscience, Inc.

DARE Healthcare Biotechnology

Dare Bioscience, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 million, up 10,412.2% from fiscal 2024. In the quarter to June 2026, revenue grew 984.4%, EPS grew 55.6% and free cash flow fell 30.2%, each against the same quarter a year earlier.

0.72 0.02 −2.70%
Market cap
$14.6M
P/E
0.0×
Fwd P/E
−2.0×
Dividend yield
—
F-score
4/9
Altman Z
−8.92
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
— 4 4 —

+8 more TTM periods

ROE
165.29% 272.28% 845.52% (2,543.18%)
ROA
(62.16%) (51.76%) (49.10%) (71.56%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(928.44%) (604.34%) (271.40%) (320.73%)
Average Days of Receivables
121.95 216.92 203.05 (2,360.03)
Free Cash Flow per Share
(0.78) (0.68) (0.92) (0.53)
Free Cash Flow
(11.60) (9.94) (10.27) (6.77)
Capital Expenditures
(0.31) — (0.39) (0.74)
Other line items
Cash ROIC
(96.22%) (51.60%) (37.28%) (25.92%)
Accounts Receivable Turnover
4.24 2.92 2.57 (0.13)
Accounts Payable Turnover
0.46 0.17 0.00 0.00
Inventory Turnover
0.00 0.00 — —
Average Days of Payables
479.19 1,696.95 0.00 0.00
Days of Inventory on Hand
0.00 0.00 — —
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
197.64% 335.82% 536.15% (14,426.44%)
Selling, General and Administrative Expense of Revenue
652.90% 751.99% 850.65% (16,081.26%)
Share Based Compensation of Revenue
109.95% 136.03% 145.27% (2,852.36%)
Operating CF/Net income
1.03 0.83 0.74 0.34
Depreciation/Fixed assets
1.50 1.39 1.05 0.74
Capex/Depreciation
(0.14) 0.00 (0.24) (0.61)
Revenue per Share
0.09 0.08 0.09 0.00
Operating CF per Share
(0.76) (0.68) (0.88) (0.47)
Capex per Share
(0.02) 0.00 (0.03) (0.06)
Capex to Sales
0.23 0.00 0.37 (12.98)

Fold the line items

Columns are period end dates